

Factors Affecting Vitamin D Level in Antiretroviral Treatment Naive Persons Living with HIV

İmran İçel Yıldırım¹, Serpil Erol¹, Derya Öztürk Engin¹, Gözde Akkiraz Baç¹,
Handan Ankaralı², Sebahat Aksaray³

¹Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Türkiye, Haydarpasa Numune Training and Research Hospital, Istanbul, Türkiye

²Department of Biostatistics, Medeniyet University, Göztepe Training and Research Hospital, Istanbul, Türkiye

³Department of Medical Microbiology, University of Health Sciences Türkiye, Haydarpasa Numune Training and Research Hospital, Istanbul, Türkiye

Abstract

Introduction: In this study, it was aimed to investigate the factors affecting vitamin D levels in antiretroviral treatment naive persons living with HIV.

Methods: This retrospective study, which included 100 patients, was performed in the Department of Infectious Diseases and Clinical Microbiology, Haydarpasa Numune Training and Research Hospital. The relationship between patients' 25(OH)D vitamin levels and demographic characteristics, underlying diseases, coinfection or malignancy, possible transmission time of HIV infection, substance use, smoking and alcohol use, CD4+ T lymphocyte counts, HIV RNA levels, and laboratory values were investigated.

Results: Of the 100 patients included in the study, 90 (90%) were male, and the mean age was 36.7±11.5. At the time of admission, 84 patients (84%) had either vitamin D deficiency or insufficiency. For between-group differences, the patients were divided into two groups based on a 25(OH)D level of <30 ng/ml and ≥30 ng/ml. The two groups were similar with respect to age, body mass index, comorbidities, sex, smoking status, alcohol use, and possible transmission time of HIV infection ($p>0.05$). Except for the ALT level ($p<0.05$), the two groups were similar with respect to all laboratory variables.

Discussion and Conclusion: This study found that antiretroviral treatment naive persons living with HIV, with and without vitamin D deficiency, showed similar characteristics with respect to some traditional risk factors such as age, gender, and obesity. However, only significant correlations were found between ALT and vitamin D levels. More studies are needed to show the relationship between ALT and vitamin D levels.

Keywords: HIV; risk factors; vitamin D level.

Vitamin D is crucial to calcium homeostasis and bone metabolism^[1]. Vitamin D deficiency is a global public health problem and has been associated with a wide variety of conditions, including osteoporosis,

hypertension, insulin resistance, cardiovascular disease, diabetes, metabolic syndrome, dyslipidemia, immune system disorder, malignancy, and impaired neurocognitive function^[1-3].


Correspondence: İmran İçel Yıldırım, M.D. Department of Infectious Diseases and Clinical Microbiology, University of Health Sciences Türkiye, Haydarpasa Numune Training and Research Hospital, Istanbul, Türkiye

Phone: +90 532 656 20 84 **E-mail:** dr.imranicel@hotmail.com

Submitted Date: 04.01.2023 **Revised Date:** 22.03.2023 **Accepted Date:** 26.03.2023

Copyright 2024 Haydarpasa Numune Medical Journal

OPEN ACCESS This is an open access article under the CC BY-NC license (<http://creativecommons.org/licenses/by-nc/4.0/>).



Serum 25-hydroxyvitamin D (25[OH]D) level is the best indicator to determine vitamin D status. There is a consensus that the 25(OH)D levels required for calcium homeostasis and healthy bone metabolism should at least be 30-32 ng/mL^[1]. Vitamin D deficiency is associated with having dark skin, decreased exposure to sunlight, hepatic failure, obesity, advanced age, adverse drug effects, and a diet poor in vitamin D^[2,3]. Vitamin D deficiency is commonly identified in both the overall population and people infected with human immunodeficiency virus (HIV)^[4]. The rate of vitamin D deficiency among HIV-infected patients varies from 12% to 100%^[5]. Middle-aged patients infected with HIV are at risk for many comorbidities that are typically similar to those observed in the elderly, including osteoporosis, diabetes, fragility fractures, cardiovascular disease, and cognitive impairment, many of which are accompanied by vitamin D deficiency. Low levels of 25(OH)D have been associated with HIV-related complications and the progression of HIV^[11].

Vitamin D deficiency among HIV-infected patients is attributed to defects in renal hydroxylation and excessive metabolic use of vitamin D^[6]. This study aimed to determine vitamin D status among newly diagnosed HIV-infected patients in whom antiretroviral therapy had not been initiated and to investigate the factors affecting 25(OH)D levels.

Materials and Methods

This retrospective study was conducted in the Infectious Diseases and Clinical Microbiology Clinic of a Training and Research Hospital, between January 1, 2015 and October 1, 2016. Data were retrieved from follow-up files and hospital records. The study included 100 HIV-infected patients aged 18 years or older who were followed up by the outpatient clinic. Patients who had not received antiretroviral therapy or vitamin D replacement therapy before and whose vitamin D level was checked at the time of admission were included in the study. The study was approved by the institutional Clinical Research Ethics Committee (HNEAH KAEK 2016/KK/100). The study protocol complies with the ethical criteria of the 1964 Declaration of Helsinki.

Demographic characteristics, underlying diseases, substance abuse, possible transmission time of HIV infection, predicted risk factors for vitamin D deficiency, and signs and symptoms related to vitamin D deficiency were examined. In addition, the baseline hemogram and biochemical values, CD4+ T lymphocyte counts (cell/

mm³), HIV RNA levels (IU/ml), and 25(OH)D levels (ng/ml) were evaluated. 25(OH)D was measured using the CMIA (Chemiluminescent Microparticle Immunoassay) technology with flexible test protocols called Chemiflex (Architect-Aeroset-Abbott Diagnostics, IL, USA).

Cut-off values of 25(OH)D for vitamin D deficiency and insufficiency were <20 ng/ml and 20 to 29 ng/ml, respectively. Higher levels (≥ 30 ng/ml) were considered sufficient^[7,8,9]. The staging of HIV infection was made according to the CDC criteria^[10,11]. Body mass index (BMI) was classified according to the World Health Organization (0-18.4 kg/m² underweight, 18.5-24.9 kg/m² normal weight, 25.0-29.9 kg/m² overweight, 30.0-34.9 kg/m² class I obesity, 35.0-39.9 kg/m² class II obesity, and 40.0 kg/m² and above class III obesity)^[12].

Statistical Analysis

Data were processed using the MedCalc Statistical Software version 12.7.7 (MedCalc Software bvba, Ostend, Belgium; <http://www.medcalc.org>; 2013). Descriptive statistics were used to express continuous variables (mean, standard deviation, minimum, median, maximum). Comparison of normally distributed continuous variables was made with the Student's t-test and the Mann-Whitney U test was used for comparison of variables that were not normally distributed. Categorical variables were compared using the chi-squared test or Fisher's Exact test where appropriate. A p value of less than 0.05 was considered statistically significant.

Results

Of 100 patients, 90 (90%) were males. The mean age was 36.7 $\pm$ 11.5 years (min-max: 18-72). Based on BMI measurements, four patients (4%) were underweight, 61 (61%) had normal weight, 31 (31%) were overweight, three (3%) had class I obesity, and one (1%) had class II obesity.

The mean 25(OH)D level was 19.9 $\pm$ 11.6 ng/ml (min-max: 3.9-83.7). The majority of patients (n=60; 60%) had a 25(OH)D level of ≤ 20 ng/ml; 24 (24%) had a 25(OH)D level of 21-29 ng/ml; and 16 (16%) had a 25(OH)D level of ≥ 30 ng/ml. Overall, 84 patients (84%) had either vitamin D deficiency or insufficiency.

For between-group differences, the patients were divided into two groups based on a 25(OH)D level of <30 ng/ml and ≥ 30 ng/ml. The two groups were similar with respect to age, BMI, comorbidities, sex, smoking status, alcohol use, and possible transmission time of HIV infection (p>0.05).

Table 1. Distribution of age and BMI based on 25(OH)D levels

	25(OH)D levels (ng/ml)	N	Mean	SD	Min	Max	p*
Age	≥30	16	40.38	12.654	24	69	0.158
	<30	84	36.04	11.211	18	72	
BMI	≥30	16	24.27	2.03	21.6	27.78	0.142
	<30	84	23.46	3.71	15.62	35.38	

BMI: Body mass index; *Mann-Whitney U.

(Tables 1, 2). All the patients, except one patient who was from Iran, were Turkish citizens.

At presentation, 52 patients (52%) had symptoms and signs that might be related to vitamin D deficiency, including fatigue in 33 (33%), headache in 19 (19%), constipation or diarrhea in 15 (15%), joint pain in 14 (14%), depression in 14 (14%), muscle cramps in 11 (11%), bone pain in 9 (9%), weight gain in seven (7%), and hypertension in five (5%).

Laboratory findings are summarized in Table 3. Except for the ALT level ($p < 0.05$), the two groups were similar with respect to all laboratory variables. According to CD4+ T lymphocyte counts, 37 patients (37%) had >500 cells/ mm^3 , 41 (41%) had 200-500 cells/ mm^3 , and 22 (22%) had <200 cells/ mm^3 . Patients with a 25(OH)D level of <30 ng/ml and ≥ 30 ng/ml did not differ significantly with respect to both CD4+ T lymphocyte count and HIV RNA level ($p > 0.05$) (Table 4).

Separate analysis of CD4+ lymphocyte counts (≥ 200 and <200) and HIV RNA levels ($<100,000$ copies/ml and $\geq 100,000$ copies/ml) also showed no significant differences between the two patient groups ($p > 0.05$) (Table 5).

Thirty patients (30%) had co-infections or malignancies, including three (3%) tuberculosis infections (two lung, one miliary tuberculosis); two (2%) cytomegalovirus (CMV) infections, causing colitis and retinitis, respectively; 11 (11%) syphilis, of which, one PCP and one neurosyphilis; seven (7%) oral candidiasis; five (5%) candida esophagitis; two (2%) acute HBV infections; one molluscum contagiosum in association with a penile intraepithelial neoplasia; one disseminated Mycobacterium avium complex infection; one progressive multifocal leukoencephalopathy; one cryptococcal meningitis in association with molluscum contagiosum; one herpes zoster infection. The two patient groups were similar with respect to the incidence of co-infections or malignancies ($p > 0.05$) (Table 6).

Table 2. Distribution of comorbidities, risk factors based on 25(OH)D levels

	25(OH)D levels (ng/ml)		p*
	<30, n (%)	≥ 30 , n (%)	
Diabetes mellitus			
No	80 (95.2)	16 (100)	0.492
Yes	4 (4.8)	0 (0)	
Hypertension			
No	77 (91.7)	15 (93.8)	0.624
Yes	7 (8.3)	1 (6.2)	
Kidney disease			
No	82 (97.6)	16 (100)	0.704
Yes	2 (2.4)	0 (0)	
Chronic HBV infection			
No	82 (97.6)	14 (87.5)	0.119
Yes	2 (2.4)	2 (12.5)	
Chronic HCV infection			
No	83 (98.8)	16 (100)	0.840
Yes	1 (1.2)	0 (0)	
Psychiatric disease			
No	77 (91.7)	15 (93.8)	0.624
Yes	7 (8.3)	1 (6.2)	
Substance abuse			
No	80 (95.2)	16 (100)	0.492
Yes	4 (4.8)	0 (0)	
Cardiovascular disease			
No	79 (94)	16 (100)	0.410
Yes	5 (6)	0 (0)	
Others			
No	83 (98.8)	15 (93.8)	0.296
Yes	1 (1.2)	1 (6.2)	
Sex			
Male	74 (88.1)	16 (100)	0.160
Female	10 (11.9)	0 (0)	
Smoking status			
Non-smoker	44 (52.4)	11 (68.8)	0.176
Current smoker	40 (47.6)	5 (31.3)	
Alcohol use			
Does not drink	51 (60.7)	8 (50)	0.299
Drinks	33 (39.3)	8 (50)	
HIV transmission time			
<24 months	36 (50.7)	8 (61.5)	0.340
≥ 24 months	35 (49.3)	5 (38.5)	

Others: Asthma, benign prostatic hypertrophy; *Fisher's Exact.

Table 3. Distribution of laboratory findings based on 25(OH)D levels

	25(OH)D levels (ng/ml)	N	Mean	SD	Min	Max	p*
Hb (gr/dL)	≥30	16	14.22	2.01	8.5	16.7	0.199
	<30	84	13.7	2.01	7	16.4	
Plt (K/uL)	≥30	16	218.6	68.7	129	384	0.836
	<30	84	203.5	62.3	15	342	
WBC (K/uL)	≥30	16	312.6	1223.3	2.85	4900	0.452
	<30	84	758.6	2298.6	1.42	10000	
CRP (mg/dL)	≥30	6	1.91	2.95	0.1	7.8	0.115
	<30	57	0.487	0.79	0.1	4.8	
Protein (g/dL)	≥30	13	7.61	0.535	6.8	8.6	0.276
	<30	79	7.79	0.779	5	10	
Albumin (g/dL)	≥30	16	4.21	0.574	2.6	5	0.557
	<30	80	4.29	0.54	2.7	5.3	
AST (IU/L)	≥30	16	32.8	27.6	14	130	0.275
	<30	84	27.4	18.6	9	118	
ALT (IU/L)	≥30	16	45.89	39.6	18	177	0.014
	<30	84	37.68	91.032	6	847	
LDH (IU/L)	≥30	9	273.2	101.48	156	460	0.200
	<30	61	231.6	72.62	138	497	
Ca (mg/dL)	≥30	7	9.1	0.766	7.6	10	0.545
	<30	59	9.31	0.588	8	10.6	
P (mg/dL)	≥30	12	3.23	0.4887	2.4	4.1	0.206
	<30	71	3.51	0.6485	2.4	5.8	
ALP (IU/L)	≥30	12	110.67	108.7	42	447	0.100
	<30	64	70.53	25.31	4.1	169	
GGT (IU/L)	≥30	15	90.27	135.495	11	432	0.143
	<30	70	41.77	87.679	9	721	
BUN (mg/dL)	≥30	15	11.53	2.67	8	17	0.517
	<30	82	12.07	3.48	5	31	
Creatinine (mg/dL)	≥30	16	0.82	0.085	0.7	1	0.830
	<30	83	0.85	0.233	0.58	2.6	

WBC: Leukocyte count; CRP: C-reactive protein; AST: Aspartate aminotransferase; ALT: Alanine aminotransferase; LDH: Lactate dehydrogenase; Ca: Calcium; P: Phosphorus; ALP: Alkaline phosphatase; GGT: Gamma glutamyl transferase; BUN: Blood urea nitrogen; *Mann-Whitney-U.

Table 4. Comparison of CD4 + T lymphocyte counts and HIV RNA levels based on 25(OH)D levels

	25(OH)D levels (ng/ml)	N	Mean	SD	Min	Max	p*
HIV RNA levels (IU/ml)	≥30	16	14424960.9	33540784.7	1793	10000000	0.579
	<30	84	2850075.5	11403231.9	6746	10000000	
CD4 counts (mm ³)	≥30	16	437.1	319.1	58	1083	0.948
	<30	84	434.8	272.6	5	1190	

*Mann-Whitney U.

Table 5. Comparison of those with CD4+ T lymphocyte counts ≥200 and <200 (mm³) according to 25(OH)D levels

	25(OH)D levels (ng/ml)		p*
	<30	≥30	
CD4 + T lymphocyte counts (mm ³)			
≥200	67 (79.8)	11 (68.8)	0.252
<200	17 (20.2)	5 (31.3)	

*Fisher's Exact.

Table 6. Distribution of patients with co-infections or malignancy based on 25(OH)D levels

	25(OH)D levels (ng/ml)		p*
	<30	≥30	
Coinfection/malignancy			
No	58 (69)	12 (75)	0.454
Yes	26 (31)	4 (25)	

*Fisher's Exact.

Discussion

Being not only a global public health problem, vitamin D deficiency has also been shown to be common among HIV-infected patients^[5,13]. Vitamin D deficiency among HIV-infected patients has been reported to arise from multiple factors, and apart from the traditional risk factors, pharmacological effects of antiretroviral therapy as well as metabolic complications accompanying HIV infection raise the risk for vitamin D deficiency^[14]. Bearden et al.^[15] reported that, of 112 HIV-infected patients, 73% had a 25(OH)D level of less than 30 ng/ml. Another study found that, of 672 HIV-positive patients, 70.3% had 25(OH)D levels of less than 30 ng/ml^[1]. A study of 96 HIV-positive patients from Istanbul found a higher rate of 83.4%^[16]. In the current study, a similar rate of 84% was found among HIV-infected patients.

Obesity is a risk factor for vitamin D deficiency in HIV-infected patients. The 25(OH)D level is considered to decrease in obese patients due to its sequestration in adipose tissue. In addition, decreased outdoor activity and exposure to sunlight also reduce 25(OH)D levels in obese people^[17]. In a study of 1268 HIV-positive women, only 13% were found to have normal vitamin D status (25(OH)D >30 ng/ml). Interestingly, the rates of vitamin D deficiency/insufficiency were 54% in underweight-normal women, 62% in overweight women, and 71% in obese women; hence, the higher BMI, the more likely vitamin D deficiency^[17]. The same trend was also reported in HIV-positive patients in whom a high BMI was associated with low levels of 25(OH)D^[18]. In our study, 31% of the patients were overweight and 4% were obese, and there was no significant difference in BMI between patients having a 25(OH)D level of <30 ng/ml and ≥30 ng/ml.

Smoking has a negative effect on vitamin D metabolism, decreasing 25(OH)D levels^[19, 20]. A study of 334 antiretroviral-treated naive patients reported low 25(OH)D levels (<30 ng/ml) in 82.3%, of whom 41.3% were current smokers, showing that smoking was associated with vitamin D deficiency^[20]. In this study, nearly half of the patients (45%) were smokers, but there was no significant difference in smoking status between patients having a 25(OH)D level of <30 ng/ml and ≥30 ng/ml.

Vitamin D is known to have a significant role in immune function^[21]. Vitamin D-deficient subjects are more likely to develop inflammation, immune activation, and to have low peripheral CD4+ T cell counts^[13]. A study of 2044 HIV-positive patients found a significant relationship between CD4+ T cell count and 25(OH)D levels. Patients

with a CD4+ T cell count of <200/μl had significantly decreased 25(OH)D levels compared to those with a CD4+ T cell count of ≥200/μl (median 11.5 ng/dl vs. 14.1 ng/dl)^[22]. In contrast, Kim et al.^[23] found no relationship between CD4+ T lymphocyte counts and 25(OH)D levels. We also found no significant difference in CD4+ T lymphocyte counts between patients having a 25(OH)D level of <30 ng/ml and ≥30 ng/ml.

Vitamin D is considered to contribute to the inhibition of HIV-1 infection in T cells by increasing antiviral gene expression, decreasing viral coreceptor CCR5 on CD4+ T cells, and promoting HIV-1-restrictive CD38+ HLA-DR+ immunophenotype^[13]. Low 25(OH)D levels were found to be associated with high HIV RNA in plasma and rapid AIDS progression^[13]. Kim et al.^[23] reported a significant association between HIV viral load above 50 copies/ml and vitamin D deficiency. In contrast, Nugmanova et al.^[24] found no association between 25(OH)D and HIV RNA among 564 HIV-infected patients. We also found similar HIV RNA levels in patients having a 25(OH)D level of <30 ng/ml and ≥30 ng/ml.

Vitamin D is known to have an immunomodulatory effect on both natural and adaptive immune responses and to reduce the incidence and severity of opportunistic infections^[25-27]. Sudfeld et al.^[25] showed a strong association between vitamin D deficiency and the development of pulmonary tuberculosis and oral candidiasis among 1103 HIV-positive patients. Canuto et al.^[28] reported higher 25(OH)D levels among patients with previous opportunistic infections. Our study found no significant difference in the incidence of opportunistic infections in patients having a 25(OH)D level of <30 ng/ml and ≥30 ng/ml.

Of the laboratory findings analyzed in the current study, only the ALT level showed a significant difference between the two patient groups based on 25(OH)D level. Patients with a 25(OH)D level of ≥30 ng/ml had a higher ALT level. Dao et al.^[1] found no significant differences in ALT and AST levels between patients with and without vitamin D deficiency. Contrary to our finding, elevated liver enzyme levels in serum, including ALT, were found in a significant proportion (42.8%) of patients with vitamin D deficiency who had not received antiretroviral therapy^[27]. Elevated liver enzyme levels were attributed to vitamin D hydroxylation associated with HIV-induced liver damage^[29]. In a study by Gurbuz et al.^[30] on 50 pediatric patients with chronic liver disease, a significant improvement was observed in AST and ALT levels after vitamin D replacement. Skaaby et al.^[31] evaluated 2649 people from the general population. The

risk of having a high level of ALT, AST, or GGT tended to be higher for lower vitamin D levels, although not statistically significant.

A main limitation to this study is the small number of patients. We examined a number of parameters in HIV-positive adults in relation to 25(OH)D levels. Unlike previous studies, we found the two patient groups similar – except for ALT – as classified by the 25(OH)D level. The small patient size may have affected our findings.

Conclusion

In conclusion, vitamin D deficiency is common among HIV-infected persons, which may be associated with the disease itself or the accompanying pathologies. This study found that HIV-infected persons with and without vitamin D deficiency showed similar characteristics with respect to some traditional risk factors such as age, gender, and obesity. Increased ALT levels accompanying a normal vitamin D status (25(OH)D level of ≥ 30 ng/ml) need to be verified by further studies enrolling a large number of patients.

Ethics Committee Approval: Approval was granted by the Ethics Committee of Haydarpasa Training and Research Hospital in Istanbul, Türkiye.

Peer-review: Externally peer-reviewed.

Authorship Contributions: İ.İ.Y., D.Ö.E.; Design: İ.İ.Y., D.Ö.E., H.A.; Supervision: S.E., D.Ö.E., H.A.; Materials: İ.İ.Y., D.Ö.E., G.A.B., S.A.; Data Collection or Processing: İ.İ.Y., D.Ö.E., G.A.B., S.A.; Analysis or Interpretation: İ.İ.Y., S.E., D.Ö.E., S.A., H.A.; Literature Search: İ.İ.Y., D.Ö.E., G.A.B.; Writing: İ.İ.Y., S.E., D.Ö.E.; Critical Review: İ.İ.Y., S.E., D.Ö.E.

Use of AI for Writing Assistance: Not declared.

Conflict of Interest: The authors have no conflicts of interest to declare that are relevant to the content of this study.

Financial Disclosure: The authors declare they have not received any research support.

References

1. Dao CN, Patel P, Overton ET, Rhame F, Pals SL, Johnson C, et al. Low vitamin D among HIV-infected adults: Prevalence of and risk factors for low vitamin D Levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. *Clin Infect Dis* 2011;52:396–405.
2. Holick MF. The vitamin D deficiency pandemic: Approaches for diagnosis, treatment and prevention. *Rev Endocr Metab Disord* 2017;18:153–65.
3. Zhang L, Tin A, Brown TT, Margolick JB, Witt MD, Palella FJ Jr, et al. Vitamin D deficiency and metabolism in HIV-infected and HIV-uninfected men in the multicenter AIDS cohort study. *AIDS Res Hum Retroviruses* 2017;33:261–70.
4. Sherwood JE, Mesner OC, Weintrob AC, Hadigan CM, Wilkins KJ, Crum-Cianflone NF, et al. Vitamin D deficiency and its association with low bone mineral density, HIV-related factors, hospitalization, and death in a predominantly black HIV-infected cohort. *Clin Infect Dis* 2012;55:1727–36.
5. Lake JE, Adams JS. Vitamin D in HIV-infected patients. *Curr HIV/AIDS Rep* 2011;8:133–41.
6. Villamor E. A potential role for vitamin D on HIV infection? *Nutr Rev* 2006;64(5 Pt 1):226–33.
7. Holick MF, Binkley NC, Bischoff-Ferrari HA, Gordon CM, Hanley DA, Heaney RP, et al. Evaluation, treatment, and prevention of vitamin D deficiency: An endocrine society clinical practice guideline. *J Clin Endocrinol Metab* 2011;96:1911–30.
8. Wacker M, Holick MF. Vitamin D - effects on skeletal and extraskelatal health and the need for supplementation. *Nutrients* 2013;5:111–48.
9. Fidan F, Alkan B, Tosun A. Pandemic era: Vitamin D deficiency and insufficiency. *Turk J Osteoporos* 2014;20:71–4.
10. Castro KG, Ward JW, Slutsker L, Buehler JW, Jaffe HW, Berkelman RL, et al. 1993 Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/00018871.htm> Accessed Mar 14, 2024.
11. Schneider E, Whitmore S, Glynn KM, Dominguez K, Mitsch A, McKenna MT. Revised surveillance case definitions for HIV infection among adults, adolescents, and children aged <18 months and for HIV infection and AIDS among children aged 18 months to <13 years-United States, 2008. Available at: <https://www.cdc.gov/mmwr/preview/mmwrhtml/rr5710a1.htm> Accessed Mar 14, 2024.
12. WHO. Global Database on Body Mass Index, BMI classification 2017. Available at: <https://www.who.int/data/gho/data/themes/topics/topic-details/GHO/body-mass-index> Accessed Mar 14, 2024.
13. Jiménez-Sousa MÁ, Martínez I, Medrano LM, Fernández-Rodríguez A, Resino S. Vitamin D in human immunodeficiency virus infection: Influence on immunity and disease. *Front Immunol* 2018;9:458.
14. Gangcuangco LM, Kohorn LB, Chow DC, Keating SM, Norris PJ, Nagamine LS, et al. High 25-hydroxyvitamin D is associated with unexpectedly high plasma inflammatory markers in HIV patients on antiretroviral therapy. *Medicine Baltimore* 2016;95:e5270.
15. Bearden A, Abad C, Gangnon R, Sosman JM, Binkley N, Safdar N. Cross-sectional study of vitamin D levels, immunologic and virologic outcomes in HIV-infected adults. *J Clin Endocrinol Metab* 2013;98:1726–33.
16. Aydın OA, Karaosmanoglu HK, Karahasanoglu R, Tahmaz M, Nazlıcan O. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. *Braz J Infect Dis* 2013;17:707–11.
17. Adeyemi OM, Agniel D, French AL, Tien PC, Weber K, Glesby MJ, et al. Vitamin D deficiency in HIV-infected and un-infected

- women in the US. *J Acquir Immune Defic Syndr* 2011;57:197–204.
18. Havers F, Smeaton L, Gupte N, Detrick B, Bollinger RC, Hakim J, et al. 25-Hydroxyvitamin D insufficiency and deficiency is associated with HIV disease progression and virological failure post-antiretroviral therapy initiation in diverse multinational settings. *J Infect Dis* 2014;210:244–53.
19. Brot C, Jorgensen NR, Sorensen OH. The influence of smoking on vitamin D status and calcium metabolism. *Eur J Clin Nutr* 1999;53:920–26.
20. Allavena C, Delpierre C, Cuzin L, Rey D, Viget N, Bernard J, et al. High frequency of vitamin D deficiency in HIV-infected patients: effects of HIV-related factors and antiretroviral drugs. *J Antimicrob Chemother* 2012;67:2222–30.
21. Ross AC, Judd S, Kumari M, Hileman C, Storer N, Labbato D, et al. Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. *Antivir Ther* 2011;16:555–63..
22. Theodorou M, Sersté T, Van Gossum M, Dewit S. Factors associated with vitamin D deficiency in a population of 2044 HIV-infected patients. *Clin Nutr* 2014;33:274–9.
23. Kim JH, Gandhi V, Pseudos G Jr, Espinoza F, Park J, Sharp V. Evaluation of vitamin D levels among HIV-infected patients in New York City. *AIDS Res Hum Retroviruses* 2012;28:235–41.
24. Nugmanova Z, Patel N, Akhmetova GM, Kurmangalieva GS, Abdumananova MK, Akanov AA, et al. Relationship between vitamin D and human immunodeficiency virus (HIV) viral load among HIV-infected patients in Kazakhstan. *J Infect Dev Ctries* 2015;9:1277–83.
25. Sudfeld CR, Giovannucci EL, Isanaka S, Aboud S, Mugusi FM, Wang M, et al. Vitamin D status and incidence of pulmonary tuberculosis, opportunistic infections, and wasting among HIV-infected Tanzanian adults initiating antiretroviral therapy. *J Infect Dis* 2013;207:378–85.
26. Bergqvist C, Ezzedine K. Vitamin D and the skin: What should a dermatologist know? *G Ital Dermatol Venereol* 2019;154:669–80.
27. Bilezikian JP, Bikle D, Hewison M, Lazaretti-Castro M, Formenti AM, Gupta A, et al. Mechanisms in endocrinology: Vitamin D and COVID-19. *Eur J Endocrinol* 2020;183:R133–R47.
28. Canuto JM, Canuto VM, de Lima MH, de Omena AL, Morais TM, Paiva AM, et al. Risk factors associated with hypovitaminosis D in HIV/aids-infected adults. *Arch Endocrinol Metab* [Article in Portuguese] 2015;59:34–41.
29. Gichuhi CW, Kariuki D, Nyerere A, Riyat M. Studies on vitamin D levels in serum of HIV infected patients: Their effect on progression towards AIDS. *World J AIDS* 2014;4:422–29.
30. Gurbuz F, Agin M, Mengen E, Elci H, Unal I, Tumgor G, et al. Vitamin D levels of children with chronic liver disease. *Cukurova Med J* [Article in Turkish] 2018;43:450–6.
31. Skaaby T, Husemoen LL, Borglykke A, Jørgensen T, Thuesen BH, Pisinger C et al. Vitamin D status, liver enzymes and incident liver disease and mortality: A general population study. *Endocrine* 2014;47:213–20.